Medico Remedies Ltd is Rated Hold by MarketsMOJO

Understanding the Current Rating

MarketsMOJO's 'Hold' rating for Medico Remedies Ltd indicates a neutral stance on the stock, suggesting that investors should neither aggressively buy nor sell at this juncture. This rating reflects a balanced view of the company's prospects, where strengths in certain areas are offset by challenges in others. The rating was adjusted on 26 August 2026, moving from a previous 'Sell' grade, signalling an improvement in the company's overall profile.

Quality Assessment

As of 11 September 2026, Medico Remedies Ltd demonstrates a good quality grade. The company has shown a strong ability to service its debt, with a low Debt to EBITDA ratio of 0.82 times, indicating prudent financial management and manageable leverage. Additionally, the firm has reported positive results for six consecutive quarters, underscoring consistent operational performance. The operating profit has grown at an impressive annual rate of 36.46%, reflecting robust business growth and effective cost control measures.

Valuation Perspective

The valuation grade for Medico Remedies Ltd is currently deemed attractive. The stock trades at a discount relative to its peers' historical valuations, supported by a Return on Capital Employed (ROCE) of 13.6% and an Enterprise Value to Capital Employed ratio of 3.4. These metrics suggest that the company is generating reasonable returns on its capital base while being valued favourably by the market. The Price/Earnings to Growth (PEG) ratio stands at 0.6, indicating that the stock may be undervalued relative to its earnings growth potential.

Financial Trend Analysis

Currently, the company's financial metrics indicate a positive financial trend. Net sales for the latest six months have grown by 58.65% to ₹126.21 crores, while Profit After Tax (PAT) has increased by 36.04% to ₹8.38 crores over the same period. Despite these encouraging figures, the stock has underperformed the benchmark BSE500 index consistently over the past three years. The stock's return over the last one year is -9.77%, and year-to-date returns stand at -30.42%, reflecting market challenges and investor caution.

Technical Outlook

The technical grade for Medico Remedies Ltd is currently bearish. Recent price action shows a decline of 2.28% on the day of analysis, with one-month and three-month returns at -22.66% and -14.84% respectively. This downward momentum suggests that the stock faces resistance in the near term, possibly due to broader market sentiment or sector-specific pressures within Pharmaceuticals & Biotechnology. Investors should be mindful of this technical weakness when considering entry or exit points.

Stock Returns and Market Performance

As of 11 September 2026, Medico Remedies Ltd has delivered mixed returns. While the stock has generated a negative return of -9.77% over the past year and -30.42% year-to-date, its underlying profits have risen by 33.8% during the same period. This divergence between earnings growth and stock price performance highlights a valuation gap that may present opportunities for patient investors. However, the consistent underperformance against the BSE500 index over three consecutive years warrants caution.

Shareholding and Corporate Profile

The company remains a microcap within the Pharmaceuticals & Biotechnology sector, with promoters holding the majority stake. This concentrated ownership can provide stability in strategic decision-making but may also limit liquidity in the stock. Investors should consider this factor alongside the company's fundamentals and market dynamics.

What the Hold Rating Means for Investors

The 'Hold' rating suggests that Medico Remedies Ltd currently offers neither a compelling buy opportunity nor a strong sell signal. Investors should weigh the company's solid fundamentals and attractive valuation against its recent price weakness and technical challenges. For those already holding the stock, it may be prudent to maintain their position while monitoring market developments and quarterly results closely. Prospective investors might consider waiting for clearer signs of technical recovery or further fundamental improvements before initiating new positions.

Sector and Market Context

Within the Pharmaceuticals & Biotechnology sector, Medico Remedies Ltd operates in a competitive environment where innovation, regulatory approvals, and market access play critical roles. The company's recent growth in sales and profits is encouraging, but the broader sector volatility and microcap status contribute to price fluctuations. Investors should consider sector trends and peer performance when evaluating this stock.

Summary of Key Metrics as of 11 September 2026

- Market Capitalisation: Microcap segment
- Mojo Score: 50.0 (Hold grade)
- Debt to EBITDA: 0.82 times (low leverage)
- Operating Profit Growth: 36.46% annualised
- Net Sales Growth (6 months): 58.65% to ₹126.21 crores
- PAT Growth (6 months): 36.04% to ₹8.38 crores
- ROCE: 13.6%
- Enterprise Value to Capital Employed: 3.4
- PEG Ratio: 0.6
- 1 Year Stock Return: -9.77%
- YTD Stock Return: -30.42%
- Technical Grade: Bearish

These figures collectively underpin the current 'Hold' rating, reflecting a company with solid financial health and growth prospects but facing near-term market headwinds and valuation uncertainties.

Investor Takeaway

Medico Remedies Ltd's current rating of 'Hold' by MarketsMOJO, updated on 26 August 2026, is a balanced reflection of its present-day fundamentals and market conditions as of 11 September 2026. Investors should appreciate the company's strong earnings growth and attractive valuation while remaining cautious about the stock's recent price weakness and technical signals. A measured approach, with attention to upcoming quarterly results and sector developments, is advisable for those considering exposure to this pharmaceutical microcap.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today